BioN­Tech, Du­al­i­ty­Bio steer ADC in­to PhI­II, with aim to com­pete in HER2-low sub­group with En­her­tu

BioN­Tech is step­ping on As­traZeneca and Dai­ichi Sankyo’s turf with the launch of a Phase III tri­al for its an­ti­body-drug con­ju­gate aim­ing at a sub­set …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.